Study attempts to find out how India made expensive diabetes medicines affordable
India’s low medication prices are tied to its role as a major pharmaceutical exporter, supported by legislation that prevents ‘patent evergreening’ and enables generic drug manufacturing, says a study by diabetologists
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
A recent study published in the journal 'Diabetes Care' by Chennai-based diabetologists analyzes how India has successfully reduced the prices of new and expensive diabetes drugs. The study highlights India's strategic legislative history, focusing on generic drug manufacturing and preventing 'patent evergreening,' as key factors in maintaining affordable medication. The findings offer valuable lessons for other low- and middle-income countries (LMICs) grappling with the high costs of managing chronic diseases like diabetes.
UPSC Perspectives
Economic
The study highlights India's critical role as the 'pharmacy of the world' due to its robust domestic manufacturing capacity for generic drugs. The core economic concept here is market competition driving down prices. When multiple domestic manufacturers enter the market following the expiration of a patent, the price of previously expensive drugs, like semaglutide, drops significantly. To support this, the government uses initiatives like (PLI) to boost domestic manufacturing of (APIs), reducing reliance on imports. However, challenges remain, such as the high absolute monthly costs of modern diabetes drugs (like SGLT2i and GLP-1 RA) relative to average household income in India, and the fact that these are often not covered by insurance. For UPSC, understand the economics of the pharmaceutical industry: how patent monopolies affect pricing, the role of generic competition in lowering costs, and the impact of government subsidies (like PLI) on supply chain resilience.
Governance
India's success in providing affordable medicines is rooted in its legal and regulatory framework. A critical safeguard mentioned is the prevention of patent evergreening, a practice where pharmaceutical companies make minor modifications to existing drugs to extend their patent life and maintain a monopoly. is a landmark provision that restricts the patentability of known substances unless they show significantly enhanced efficacy, thereby facilitating the early entry of generic alternatives. Furthermore, deliberate distribution strategies like the (PMBJP) through Jan Aushadhi Kendras ensure these generic drugs reach the masses at affordable retail prices. However, governance challenges persist, including urban-rural disparities in distribution, maintaining strict pharmacovigilance (monitoring drug safety), and ensuring the quality of generic medicines. UPSC questions often focus on the balance between rewarding innovation (through patents) and ensuring public health access, analyzing the effectiveness of schemes like PMBJP, and evaluating India's patent regime.
Social
Diabetes is a chronic condition requiring lifelong care, making affordability a major barrier to effective management, especially in LMICs where 80% of adults with diabetes reside. The study notes that essential, older drugs like metformin and sulfonylureas form the foundation of management and are included in the (NLEM), ensuring their availability and affordability. However, newer, more effective therapies are not yet on this list. This raises the issue of health equity—ensuring all sections of society have access to the best available treatments. The lack of comprehensive health insurance coverage for outpatient care and medications in India means the financial burden falls heavily on households through out-of-pocket expenditure. The study's recommendations for LMICs—building local manufacturing, predictable price regulation, and aligning pharmaceutical policy with health financing—are essentially strategies to achieve (UHC). For the exam, connect drug pricing to the broader issue of healthcare access, the role of the NLEM, and the challenge of reducing out-of-pocket health expenses in India.